Medicare Enrolled
Dr. Michael Russoniello, MD
Pulmonary Disease · Denville, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Russoniello from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Russoniello?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Russoniello
Dr. Michael Russoniello is a pulmonary disease specialist in Denville, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Russoniello performed 2,743 Medicare services across 1,337 unique beneficiaries.
Between the years covered by Open Payments, Dr. Russoniello received a total of $5,663 from 44 pharmaceutical and/or device companies across 348 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Russoniello is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 20% volume in NJ
$5,663 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,743
Medicare services
Top 20% in NJ for pulmonary disease
1,337
Unique beneficiaries
$98
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~137 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
799 | $100 | $167 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
586 | $102 | $217 |
| Nursing facility ventilation assistance and management This service involves the assistance and management of a patient's breathing support within a nursing facility setting. |
409 | $38 | $79 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
357 | $179 | $468 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
166 | $135 | $323 |
| Airflow rate measurement test A test that measures the rate of airflow. This procedure assesses how quickly air moves. |
110 | $32 | $68 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
110 | $136 | $282 |
| Albuterol inhalation solution, 1 mg A unit dose of FDA-approved albuterol solution administered via durable medical equipment for inhalation. |
51 | $0 | $5 |
| Inpatient or observation ventilation management Follow-up care for a patient receiving ventilator support during an inpatient stay or observation period. This service involves the ongoing management and adjustment of breathing assistance. |
50 | $50 | $107 |
| Transitional care management services, moderate complexity Services provided to coordinate care during the transition from an inpatient or other facility setting back to the community. This includes follow-up and management of a health problem of at least moderate complexity. |
22 | $180 | $352 |
| Insertion of non-tunneled central venous catheter A procedure to place a central venous catheter for infusion in patients aged 5 years or older. The catheter is inserted directly into a large vein without being tunneled under the skin. |
18 | $71 | $185 |
| Ultrasound guidance for blood vessel access Use of ultrasound imaging to help locate and access a blood vessel. This guidance assists healthcare providers in performing procedures such as inserting IV lines or drawing blood. |
18 | $12 | $28 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
18 | $34 | $101 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
16 | $16 | $33 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
13 | $27 | $57 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.7% high complexity
1.1% medium
98.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,663
Total received (2018-2024)
Avg $809/year across 7 years
Top 26% in NJ for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
44
Companies
348
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,644 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$18 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$256
2023
$1,516
2022
$1,135
2021
$823
2020
$602
2019
$637
2018
$693
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$48
Mylan Specialty L.P.
$36
Boehringer Ingelheim Pharmaceuticals, Inc.
$33
AstraZeneca Pharmaceuticals LP
$31
Itamar Medical Inc
$29
GENZYME CORPORATION
$18
Lilly USA, LLC
$17
Alkermes, Inc.
$16
Takeda Pharmaceuticals U.S.A., Inc.
$15
Novo Nordisk Inc
$14
Top 3 companies account for 45.7% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,295
GlaxoSmithKline, LLC.
$1,220
Boehringer Ingelheim Pharmaceuticals, Inc.
$876
Mylan Specialty L.P.
$305
Regeneron Healthcare Solutions, Inc.
$214
Philips Electronics North America Corporation
$207
Takeda Pharmaceuticals U.S.A., Inc.
$149
Grifols USA, LLC
$123
JAZZ PHARMACEUTICALS INC.
$110
Covis Pharma GmBH
$92
Teva Pharmaceuticals USA, Inc.
$91
Merck Sharp & Dohme Corporation
$83
Sunovion Pharmaceuticals Inc.
$67
GENZYME CORPORATION
$61
Harmony Biosciences LLC
$55
Shire North American Group Inc
$52
Advanced Respiratory, Inc
$51
United Therapeutics Corporation
$48
Insmed, Inc.
$45
Bayer HealthCare Pharmaceuticals Inc.
$35
OptiNose US, Inc.
$32
Actelion Pharmaceuticals US, Inc.
$32
Inogen, Inc.
$29
Itamar Medical Inc
$29
Jazz Pharmaceuticals Inc.
$29
Axsome Therapeutics, Inc.
$28
Janssen Pharmaceuticals, Inc
$28
Electromed, Inc.
$25
Inspire Medical Systems, Inc.
$23
Genentech USA, Inc.
$19
Mallinckrodt Hospital Products Inc.
$17
Baxter Healthcare
$17
Lilly USA, LLC
$17
Alkermes, Inc.
$16
Merck Sharp & Dohme LLC
$15
Amgen Inc.
$15
Horizon Therapeutics plc
$15
PFIZER INC.
$14
Novo Nordisk Inc
$14
Optinose US, Inc.
$14
ADVANCED RESPIRATORY, INC
$14
kaleo, Inc.
$14
Paratek Pharmaceuticals, Inc.
$13
Mallinckrodt Enterprises LLC
$13
Top 3 companies account for 59.9% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · AIRSUPRA · ALVESCO · ANORO · ARALAST · AREXVY · ASMANEX · AUVI-Q · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CINQAIR · CUVITRU · DIFICID · DUPIXENT · Dymista · ELIQUIS · Esbriet · FASENRA · GLASSIA · Hillrom - Life 2000 Ventilation System · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INSPIRE · LONHALA MAGNAIR · MOUNJARO · NUCALA · NUZYRA · OFEV · OPSUMIT · Prolastin-C · Prolastin-C Liquid · RAYOS · SHINGRIX · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Sunosi · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Utibron · VIVITROL · WAKIX · Wakix · WatchPATONE · Wegovy · XARELTO · XYWAV · Xhance · Xyrem · YUPELRI · Yupelri · ZERBAXA · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
157
Per 100K population
30.8
County median income
$134,929
Nearest hospital
SAINT CLARE'S HOSPITAL/ DENVILLE CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Russoniello is a clinical cardiology specialist, with above-average Medicare volume (top 20% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Russoniello experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Russoniello performed 799 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Russoniello receive payments from pharmaceutical companies?
Yes. Dr. Russoniello received a total of $5,663 from 44 companies across 348 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Russoniello's costs compare to other pulmonary diseases in Denville?
Dr. Russoniello's average Medicare payment per service is $98. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Russoniello) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Denville
Browse pulmonary diseases in Denville ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NJ
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NJ
Which NJ pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology